Clinical characteristics and biological parameters in temperamental clusters of suicide attempters

被引:36
作者
Engstrom, G
Alling, C
Gustavsson, P
Oreland, L
TraskmanBendz, L
机构
[1] UNIV LUND HOSP, DEPT MED NEUROCHEM, S-22185 LUND, SWEDEN
[2] KAROLINSKA INST, DEPT CLIN NEUROSCI, STOCKHOLM, SWEDEN
[3] UPPSALA UNIV, DEPT MED PHARMACOL, UPPSALA, SWEDEN
关键词
temperament; suicide attempts; depression; monoamine metabolites; monoamine oxidase; dexamethasone;
D O I
10.1016/S0165-0327(97)00029-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A sample of 215 suicide attempters was categorized in a cluster analysis into four groups according to temperamental traits. Monoamine metabolites in the cerebrospinal fluid were analysed (n = 106). Dexamethasone suppression tests (DST) were performed (n = 154) and the activity of the enzyme monoamine oxidase in platelets (pl-MAO) was assessed (n = 103). Patients belonging to the two clusters with the most deviant temperament profiles (nos 2 and 3) were young and scored high on the Beck Hopelessness Scale and the Suicide Assessment Scale. ''Cluster 3'' (''neurotic, impulsive, aggressive'') patients often had dysthymia and axis II, cluster B diagnoses (e.g. borderline or histrionic personality). ''Cluster 2'' (''neurotic and introverted'') patients often had major depression. The ''Cluster 1'', with on the whole a normal temperament profile, had significantly higher levels of post-DST cortisol than the other clusters. The ''Cluster 4'' had a normal temperament profile. Adjustment disorders were most common in ''Cluster 1'' and ''Cluster 4''. The monoamine metabolite levels did not differ between the clusters, and the differences in pl-MAO activity disappeared after adjusting for age and gender, The results suggest that temperament profiles in suicide attempters are related to psychiatric diagnoses, suicidality, hopelessness, and post-DST cortisol, but are not predictive of completed suicide. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:45 / 55
页数:11
相关论文
共 53 条
[41]  
Schalling D., 1993, MENTAL DISORDER CRIM, P208
[42]  
Schalling D, 1978, PSYCHOPATHIC BEHAV A, P85
[43]  
STANLEY B, 1986, PSYCHOPHARMACOL BULL, V22, P200
[44]  
STEER RA, 1993, J CLIN PSYCHOL, V49, P603, DOI 10.1002/1097-4679(199309)49:5<603::AID-JCLP2270490502>3.0.CO
[45]  
2-Y
[46]  
TRASKMAN L, 1981, ARCH GEN PSYCHIAT, V38, P631
[47]  
TRASKMANBENDZ L, 1992, J CLIN PSYCHOPHARM, V12, pS21
[48]  
VIRKKUNEN M, 1994, ARCH GEN PSYCHIAT, V51, P28
[49]  
VIRKKUNEN M, 1994, ARCH GEN PSYCHIAT, V51, P20
[50]  
VONKNORRING AL, 1985, ACTA PSYCHIAT SCAND, V72, P51